Alembic Pharmaceuticals has received final USFDA approval for Ivabradine tablets, aimed at reducing hospitalisations due to heart failure. Shares rose over 1.3% following the announcement, reflecting market optimism.
Alembic Pharmaceuticals has received final USFDA approval for Ivabradine tablets, aimed at reducing hospitalisations due to heart failure. Shares rose over 1.3% following the announcement, reflecting market optimism.